Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker TLPH · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 15, 2025 | Nafamostat Efficacy in Phase 3 Registrational CRRT Study NCT06150742 · Acute Kidney Injury Niyad (nafamostat mesylate), Placebo (0.9% NaCl) | TLPH Talphera, Inc | Not applicable | Recruiting | 70 | Dec 2025 | Registry ↗ |
| Aug 8, 2018 | Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet Syst… NCT02662764 · Moderate-to-severe Acute Pain Zalviso™ 15 mcg | TLPH Talphera, Inc | Phase 3 | Completed | 320 | Apr 14, 2017 | Registry ↗ |
| Jul 17, 2018 | Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects NCT02082236 · Healthy Treatment Arm A: Sufenta®, Treatment B: Sufentanil SSM 30 m… | TLPH Talphera, Inc | Phase 1 | Completed | 40 | May 2014 | Registry ↗ |
| Oct 19, 2017 | Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain NCT02447848 · Moderate-to-severe Acute Pain sufentanil sublingual 30 mcg tablet | TLPH Talphera, Inc | Phase 3 | Completed | 76 | Jun 2016 | Registry ↗ |
| Mar 15, 2017 | A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Ta… NCT02662556 · Acute Moderate-to-severe Pain sufentanil sublingual tablet 30 mcg | TLPH Talphera, Inc | Phase 3 | Completed | 140 | Jun 2016 | Registry ↗ |
| Feb 13, 2017 | A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Oper… NCT02356588 · Post-Operative Pain Sufentanil Tablet 30 mcg, Placebo Tablet | TLPH Talphera, Inc | Phase 3 | Completed | 161 | Jun 2015 | Registry ↗ |
| Nov 4, 2016 | Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics NCT01721070 · Pharmacokinetics Sufentanil NanoTab (SUF NT) 15 mcg, Ketoconazole 400 mg, su… | TLPH Talphera, Inc | Phase 1 | Completed | 19 | Dec 2012 | Registry ↗ |
| Oct 20, 2015 | Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post… NCT01660763 · Post Operative Pain Sufentanil NanoTab PCA System/15 mcg, Placebo Sufentanil Na… | TLPH Talphera, Inc | Phase 3 | Completed | 419 | Apr 2013 | Registry ↗ |
| Oct 20, 2015 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safe… NCT01539642 · Post-Operative Pain Sufentanil NanoTab PCA System/15 mcg, Placebo Sufentanil Na… | TLPH Talphera, Inc | Phase 3 | Completed | 172 | Jan 2013 | Registry ↗ |
| Oct 1, 2015 | Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab NCT01761565 · Plasma Concentrations Single dose of SUF NT 15 mcg, 40 consecutive doses of SUF N… | TLPH Talphera, Inc | Phase 1 | Completed | 40 | Feb 2013 | Registry ↗ |
| Oct 1, 2015 | Effect of Delivery Route on PK of Sufentanil NanoTab NCT01639729 · Pharmacokinetics Treatment A: Sufentanil IV, Treatment B: Sufentanil NanoTab… | TLPH Talphera, Inc | Phase 1 | Completed | 25 | Jul 2012 | Registry ↗ |
| Oct 1, 2015 | A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of t… NCT01539538 · Post-Operative Pain Sufentanil NanoTab PCA System/15 mcg, morphine IV PCA | TLPH Talphera, Inc | Phase 3 | Completed | 357 | Dec 2012 | Registry ↗ |
| Jan 26, 2015 | Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy NCT01710345 · Acute Pain Sufentanil NanoTab 20 mcg, Sufentanil NanoTab 30 mcg | TLPH Talphera, Inc | Phase 2 | Completed | 101 | Feb 2013 | Registry ↗ |
| Jan 22, 2015 | A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safe… NCT00718081 · Major Upper or Lower Abdominal Surgery Oral sufentanil, Placebo | TLPH Talphera, Inc | Phase 2 | Completed | 88 | Mar 2009 | Registry ↗ |
| Jan 1, 2015 | A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab… NCT00833040 · Cancer, Pain Sublingual sufentanil NanoTabs™ and placebo NanoTabs™ | TLPH Talphera, Inc | Phase 2 | Completed | 34 | Mar 2010 | Registry ↗ |
15 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances